CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-05-25 | Goldberg Mark Alan Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2017-05-25 | Thackray Helen M. SVP Clinical Development, CMO | Sale | −2,000 | $15.57 | $31K | 152,615 |
| 2017-05-19 | Thackray Helen M. SVP Clinical Development, CMO | Sale | −2,000 | $12.14 | $24K | 154,615 |
| 2017-05-10 | Magnani John L. SVP of Research, CSO | Option exercise | +8,928 | $1.12 | $10K | 99,302 |
| 2017-05-10 | Magnani John L. SVP of Research, CSO | Option exercise · Employee Stock Option (right to buy) | −8,928 | 213,967 | ||
| 2017-03-09 | Koenig Scott Director | Grant or award · Stock Option (right to buy) | +22,000 | 22,000 | ||
| 2017-01-04 | Magnani John L. SVP of Research, CSO | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2017-01-04 | Thackray Helen M. SVP Clinical Development, CMO | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2017-01-04 | Hahn Brian M. CFO | Grant or award · Employee Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2017-01-04 | King Rachel K. President, CEO | Grant or award · Employee Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2016-12-20 | JUNIUS DANIEL M Director | Purchase | +5,000 | $6.01 | $30K | 5,000 |
| 2016-10-03 | Thackray Helen M. VP Clinical Development, CMO | Sale | −3,900 | $7.00 | $27K | 156,715 |
| 2016-10-03 | Thackray Helen M. VP Clinical Development, CMO | Sale | −100 | $7.01 | $701 | 156,615 |
| 2016-07-20 | Thackray Helen M. VP Clinical Development, CMO | Sale | −2,000 | $8.00 | $16K | 160,615 |
| 2016-07-06 | Thackray Helen M. VP Clinical Development, CMO | Sale | −6,796 | $6.68 | $45K | 162,615 |
| 2016-07-05 | Thackray Helen M. VP Clinical Development, CMO | Sale | −10,136 | $7.01 | $71K | 169,411 |
| 2016-07-01 | Thackray Helen M. VP Clinical Development, CMO | Sale | −5,068 | $7.40 | $38K | 179,547 |
| 2016-06-29 | Baldwin John J. Director | Option exercise | +605 | $1.12 | $678 | 1,210 |
| 2016-06-29 | Baldwin John J. Director | Option exercise · Stock Option (right to buy) | −605 | 0 | ||
| 2016-05-17 | PEARSON TIMOTHY R Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 |
Page 15 of 16 · 305 trades